[CL1-64315-004]-laysummary-2024.02.21.fr

Home » Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with azacitidine in patients with acute myeloid leukaemia (AML) » [CL1-64315-004]-laysummary-2024.02.21.fr

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.

Accessibility